<DOC>
	<DOC>NCT00211991</DOC>
	<brief_summary>This study answers a U.S. Food and Drug Administration requirement for evaluation in people of the consistency of manufacturing of a vaccine. Subjects are randomized to one of three lots of vaccine. The antibodies in the blood measure the immunogenicity of each lot of vaccine, and typical vaccine safety information is also collected.</brief_summary>
	<brief_title>Evaluation of Consistency of StaphVAX Manufacturing Lots</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<criteria>healthy, written informed consent, negative serum pregnancy test if appropriate, expect to comply with protocol procedures and schedule known HIV, immunomodulatory drugs, malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early stage prostate cancer), active infection in the 2 weeks prior to study injection, serious S. aureus infection within the last 3 months prior to injection, use of investigational drugs, vaccines or devices within the prior 30 days, hypersensitivity to components of StaphVAX</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>